英派药业：自主研发PARP抑制剂塞纳帕利开创卵巢癌全人群治疗新范式

Core Insights - Ovarian cancer, one of the deadliest gynecological tumors, affects approximately 50% of patients with homologous recombination deficiency (HRD) and 70%-80% of patients are BRCA wild-type, previously lacking effective treatment options [1][2] - Nanjing Inpai Pharmaceutical Co., Ltd. has focused on precision cancer therapies based on synthetic lethality since its establishment in 2009, becoming one of only three companies globally with both commercialized PARP1/2 inhibitors and clinical-stage next-generation PARP1 selective inhibitors [1][3] Group 1 - The Phase III FLAMES study results for Senaparib, a new PARP1/2 inhibitor, showed statistically significant improvement in median progression-free survival (mPFS) for patients regardless of BRCA mutation status, with a hazard ratio (HR) of 0.43 (p<0.0001), indicating a 57% reduction in the risk of disease progression or death [2] - Senaparib is one of only three PARP1/2 inhibitors approved for first-line maintenance treatment of ovarian cancer in the entire population, breaking the limitation of efficacy only for BRCA mutation patients [2] - The drug has a low incidence of non-hematological adverse events, with a permanent discontinuation rate due to adverse events of only 4.4%, and no significant hypertension risk observed, facilitating long-term treatment management [2] Group 2 - Senaparib was approved by the National Medical Products Administration of China in January 2025, becoming the first domestically approved Class 1 innovative drug in Shanghai that year [2] - Following its approval, the company quickly established a nationwide presence and partnered with a subsidiary of Huadong Medicine to build a gynecological oncology platform, accelerating market penetration [2] - The European Marketing Authorization Application (MAA) for Senaparib was accepted by the EMA in August 2025, and the company is also expanding its research into lung cancer and has received orphan drug designation from the FDA for related studies [2][3] Group 3 - Inpai Pharmaceutical's focus on independent innovation, clinical breakthroughs, and commercial success with Senaparib sets a new benchmark in ovarian cancer treatment and highlights the competitiveness of Chinese innovative pharmaceutical companies in the global precision oncology arena [3] - The company aims to continue leveraging its synthetic lethality technology platform to promote more innovative therapies, providing better and more accessible treatment options for cancer patients worldwide, contributing to the high-quality development of the biopharmaceutical industry [3]